Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Aliment Pharmacol Ther. 2010 Jan 12;31(7):719–734. doi: 10.1111/j.1365-2036.2010.04235.x

Figure 1.

Figure 1

Enrollment, Randomization, and Follow-up of Study Participants.

Patients were enrolled in either the lead-in cohort of patients who underwent another course of antiviral treatment with peginterferon and ribavirin within the study or in the express cohort of patients who were initially treated outside the study. They were then randomly assigned to either the treatment or the control group and were followed for clinical outcomes and histological evidence of progression of liver disease.